0JQ2.LSE KALA BIO, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -70.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0JQ2.LSE undervalued?
Graham numberThe Graham number of KALA BIO, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KALA BIO, Inc. fundamental analysis
No fundamental analysis for KALA BIO, Inc. yet.
KALA BIO, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KALA BIO, Inc.
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC…
Full company profileKALA BIO, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KALA BIO, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 6.07M | 6.36M | 11.2M | 3.89M | - | - | - | - |
| Gross Profit | -297K | -643K | -955K | 3.23M | 3.19M | 7.14M | 1.33M | -303K | -259K | -317K | - |
| Operating Income | -32.7M | -39.9M | -64.7M | -88.2M | -96.2M | -109M | -81.4M | -39.7M | -40.4M | -42.4M | -7.05M |
| EBITDA | -32.1M | -40.5M | -62.5M | -83.3M | -92.9M | -132M | -36.7M | -38.9M | -32.5M | -42.1M | -6.89M |
| Net Income | -33.2M | -42.2M | -66.7M | -94.3M | -104M | -143M | -44.8M | -42.2M | -38.5M | -27.0M | -6.40M |
| EPS | -70,121 | -4,302 | -6,236 | -6,895 | -4,980 | -5,468 | -1,474 | -868 | -507 | -166 | -86 |
| Balance Sheet | |||||||||||
| Total Assets | 46.3M | 117M | 221M | 154M | 222M | 139M | 86.8M | 55.9M | 55.5M | 9.49M | 10.6M |
| Total Liabilities | 15.7M | 26.9M | 116M | 125M | 122M | 123M | 67.8M | 48.4M | 43.2M | 2.49M | 1.54M |
| Shareholders' Equity | 30.6M | 89.7M | 105M | 29.7M | 100.0M | 16.8M | 19.0M | 7.50M | 12.3M | 7.00M | 9.04M |
| Cash & Short-term Investments | 45.5M | 115M | 171M | 86.1M | 154M | 93.0M | 70.5M | 50.9M | 51.2M | 7.56M | 7.23M |
| Total Debt | 9.65M | 19.1M | 99.4M | 101M | 101M | 80.2M | 43.0M | 36.3M | 32.6M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.3M | -34.1M | -54.1M | -92.7M | -90.7M | -108M | -78.9M | -27.9M | -29.4M | -32.0M | -8.86M |
| Capital Expenditure | 153K | 480K | 1.58M | 1.34M | 1.94M | 886K | 313K | 610K | 208K | 15.0K | 0.00 |
| Free Cash Flow | -27.5M | -34.6M | -55.7M | -94.1M | -92.6M | -109M | -79.2M | -28.5M | -29.6M | -32.0M | -8.86M |
| Ratios | |||||||||||
| ROE | -108.3% | -47.1% | -63.6% | -317.8% | -104.3% | -848.6% | -236.2% | -562.4% | -312.3% | -385.6% | -70.8% |
| ROA | -71.6% | -36.2% | -30.2% | -61.1% | -47.1% | -102.3% | -51.6% | -75.4% | -69.4% | -284.3% | -60.5% |
| Net Profit Margin | - | - | - | -1,553.3% | -1,639.8% | -1,268.7% | -1,151.6% | - | - | - | - |
| Debt to Equity | 0.32x | 0.21x | 0.95x | 3.41x | 1.01x | 4.77x | 2.26x | 4.84x | 2.65x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
KALA BIO, Inc. dividends
KALA BIO, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.02:1 on May 11, 2026.
Who owns KALA BIO, Inc.
- Insiders 6.24%
- Institutions 4.07%
- Public & others 89.69%
- Free float 19.3M
KALA BIO, Inc. company profile
- Company name
- KALA BIO, Inc.
- Ticker
- 0JQ2.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 1167 Massachusetts Avenue, Arlington, MA, United States, 02476
- Phone
- 781 996 5252
- Website
- kalarx.com
About KALA BIO, Inc.
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
KALA BIO, Inc. management
9- Ms. Mary Reumuth CPATreasurer & Secretary · born 1975
- Mr. Avi MinkowitzCEO, CFO & Chairman · born 1988
- Dr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory Board
- Ms. Jill S. SteierExecutive Director of Investor Relations & Corporate Communications
- Mr. Vincent KosewskiSenior VP of Manufacturing & Supply Chain Management · born 1963
- Dr. Francis S. Mah M.D.Chief Medical Advisor
- Mr. Josiah Craver CPASenior VP & Corporate Controller
- Mr. Carl RennieExecutive Director of Account Management
- Mr. Patrick BedellExecutive Director of Trade & Alternate Channels